Evonik Expands CMO Capabilities for APIs and Intermediates

News
Article

Evonik completed a EUR 36 million expansion of its contract-manufacturing capabilities for API and advanced intermediates in the United States and Germany.

Evonik completed a EUR 36-million (US$42-million) expansion of its contract manufacturing capabilities in the United States and Europe, the company announced in a Sept. 19, 2018 press release. A series of advanced technologies, including high-potency API (HPAPI), fermentation, polyethylene glycol monomethyl ethers (mPEGs), and continuous processing have been introduced or enhanced at multiple Evonik production sites over the past year.

At its facility in Hanau, Germany, Evonik has recently commissioned a new modular cGMP continuous processing plant, a pilot plant for the custom synthesis of highly pure PEGs and mPEGs for pharmaceutical applications, and a cGMP suite for the small-scale production of HPAPI and ultra-HPAPI.

At its facilities in Tippecanoe, Indiana, US and Hanau, Germany, Evonik has increased its asset footprint and added additional capacities to support the small-, medium-, or large-scale production of HPAPI. Evonik is now able to run several HPAPI projects in parallel down to an occupational exposure level of 5 ng/m³. 

At its facility in Slovakia, the company has recently invested in a new, flexible pilot plant for downstream processing. It is the sixth plant in a worldwide network to support microbial fermentation projects from strain development through to commercial manufacturing.

The Exclusive Synthesis team from Evonik will be at CPhI Worldwide in Madrid between October 9–11, 2018 at booth 9K20.

Source: Evonik

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content